Marius N. Stan, M.D.

The purpose of this study is to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.

The purpose of this study is to evaluate the efficacy of batoclimab 680 milligrams (mg) subcutaneous (SC) once a week (QW) for 12 weeks followed by 340 mg SC QW for 12 weeks versus placebo on proptosis responder rate at Week 24.

The purpose of this study is to evaluate the efficacy of IMVT-1402 as treatment for adult patient Graves' Disease.

The purpose of the observational cohort will assess the durability of proptosis response of feeder studies off treatment. The treatment cohort will evaluate the effectiveness of batoclimab as assessed by proptosis responder rate.

The purpose of this study is to examine the effects of RVT-1401 versus placebo on proptosis responder rate at week 7, and to assess the safety and tolerability of RVT-1401 in patients with active, moderate to severe Graves' Ophthalmopathy (GO).

The purpose of this study is to evaluate the safety and tolerability of linsitinib. Study drug is administered twice daily for six-months (24 weeks) in approximately 75 men and women (25 of which will be randomized to placebo) with active, moderate-to-severe Thyroid Eye Disease (TED).
 

The purpose of this study is to evaluate the safety, effectiveness and need for re-treatment of 3 different teprotumumab treatment durations for thyroid eye disease (TED). In addition, serum samples from patients with a Baseline Clinical Activity Score (CAS) ≥ 3 will be evaluated for biomarkers of disease.

Teprotumumab was approved by the United States Food and Drug Administration on 21 January 2020 for the treatment of TED under the name TEPEZZA® (teprotumumab-trbw). 

The primary purpose of this study is to investigate the effectiveness, safety and tolerability of TEPEZZA® (teprotumumab-trbw) in comparison to placebo in treating patients with chronic (inactive) TED.

The purpose of this study is to evaluate the safety and effectiveness of CFZ533 following 12 weeks of treatment in patients with Graves' disease.

The purpose of this pilot study is to evaluate the effects of Radiofrequency Ablation (RFA) on thyroid hormones to treat thyroide nodules.

Radiofrequency ablation (RFA) of thyroid nodules would locally destroy follicular thyroid cells and could possibly impart conformational changes to the chemistry of thyroid hormones, thus altering their bioactive profiles. To evaluate this phenomenon, in vitro investigations to characterize qualitative and quantitve Mass Spectrometric chromatographic profile for thyroid hormones will be performed before and after RFA from patients undergoing ablation for thyroid nodules. {If there is a blood draw for clinical tests, we would request left over specimen from clinical laboratory for research purpose and consider this pre RFA draw; only if otherwise we would have a research preRFA blood draw; for post RFA we would have exclusive research blood draw}.

This study is being done to see if better therapies can be developed to treat Graves’ disease, using new laboratory assays

The purpose of this study is to evaluate the efficiency of Radiofrequency ablation (RFA) therapy to treat papillary thyroid carcinoma.

The purpose of this study is to analyze the changes in serum thyroid hormone levels in amiodone-induced thyroiditis (AIT) patients after radiofrequency ablation (RFA) therapy on a portion of thyroid parenchyma in order to safely decrease thyroid hormone levels into the normal range with resolution of thyrotoxicosis.

Will teriparatide ( Forteo) shorten the length of hospitalization post thyroidectomy in patients with symptomatic hypoparathyroidism

The purpose of this study is to determine the placental D3 activity in a woman with RTH and compare to women without RTH because we believe this may be a potential mechanism which limits fetal thyroid hormone exposure.

The study will try to answer the question of whether early treatment with levothyroxine at 4 weeks after radioactive iodine for Graves' disease will prevent overt hypothyroidism (low thyroid hormone levels).

We plan to create a databank of serum and tissue samples from patients with thyroid autoimmunity, mainly focusing on Graves’ disease and Graves’ orbitopathy, respectively. This set of samples will allow us to study these disorders better in the laboratory as well as test potential agents that can be used as therapies.